Wednesday’s Top Biotech Stories: Orexigen, Portola, and Regeneron

Orexigen, Portola, and Regeneron could all make waves across the health care sector this Wednesday morning.

Jun 11, 2014 at 9:11AM

Longview

Let's take a look at three stocks -- Orexigen Therapeutics (NASDAQ:OREX), Portola Pharmaceuticals (NASDAQ:PTLA), and Regeneron (NASDAQ:REGN) -- which could all loom large in Wednesday's health care headlines.

Orexigen's PDUFA date for NB32/Contrave gets extended by three months
Bad news for Orexigen this morning -- the FDA just extended its PDUFA (Prescription Drug User Fee Act) date for its obesity drug candidate NB32 three months to September 11, 2014. The FDA stated that it needed the extension to reach an agreement on Orexigen's post-marketing obligations and to further evaluate the drug's cardiovascular outcomes.

Investors should note that NB32, formerly known as Contrave, was rejected back in February 2011 due to concerns about statistically significant increases in blood pressure and heart rate.

The FDA has been fairly tough on new obesity drugs, after it pulled fen-phen (fenfluramine/phentermine) -- a popular weight loss treatment in the 1990s -- off the market in 1997 after it was implicated in potentially fatal pulmonary hypertension and heart valve problems. When two newer obesity drugs -- Arena's Belviq and VIVUS' Qsymia -- were approved in 2012, they were notably the first new obesity drugs approved by the FDA in 13 years.

Orexigen does not have any marketed products, and its pipeline only consists of two experimental drugs -- NB32 and Empatic, another weight loss treatment. Analysts once predicted that NB32/Contrave could generate peak sales of $1 billion, but those projections were set before its first rejection in 2011. Shares of Orexigen are down 17% in pre-market trading this morning.

Portola rallies on positive phase 2 results for andexanet alfa
Meanwhile, Portola Pharmaceuticals just announced positive phase 2 proof-of-concept study data for andexanet alfa, a potential first-in-class Factor Xa inhibitor antidote which reverses the effects of blood thinners.

Portola reports that andexanet alfa immediately reversed the anticoagulation activity of enoxaparin, a low molecular weight blood thinner commonly used to treat venous thromboembolisms. The company stated that the treatment was well tolerated with no adverse events reported. The trial was conducted on 27 healthy volunteers given either andexanet alfa or a placebo to reverse the effects of enoxaparin. Detailed data will be presented at the 60th Scientific and Standardization Committee (SSC) Meeting of the International Society of Thrombosis and Haemostasis (ISTH) from June 23 to 26.

Portola doesn't have any marketed products. Andexanet alfa is one of the company's two most advanced clinical products -- the other one is Betrixaban, a blood thinner. Portola currently holds collaborations with Pfizer, Bayer, Bristol-Myers Squibb, Johnson & Johnson, and Daiichi Sankyo for andexanet alfa.

Shares of Portola, which have already advanced 16% over the past 12 months, are currently up 7% in pre-market trading.

Label expansion for Eylea submitted to the EMA
Last but not least, Regeneron just reported that marketing partner Bayer (NASDAQOTH:BAYRY) has submitted a marketing authorization application to the European Medicines Agency (EMA) for Eylea as a treatment for macular edema following branch retinal vein occlusion (BRVO).

Regeneron markets Eylea in the U.S. and Bayer markets the drug overseas and the companies split profits equally except for Japan, where Regeneron receives a percentage of net sales. Eylea is Regeneron's main source of revenue, accounting for more than two-thirds of its top line in 2013. Total worldwide sales of Eylea came in at nearly $1.9 billion last year, but it could still have room to climb -- analysts believe that the drug could eventually hit peak sales between $3.5 billion and $4.0 billion by 2020.

Eylea has been approved in the U.S. as a treatment for wet age-related macular degeneration (AMD) and for central retinal vein occlusion (CRVO). In Europe, it has been approved for wet AMD and macular edema following CRVO. Regulatory submissions have been made to the FDA for macular edema following BRVO and in Europe for diabetic macular edema (DME).

Of these indications, an approval for DME -- which affects 21 million people worldwide -- could be the biggest catalyst for Eylea sales, since the drug's primary competitor, Novartis' Lucentis, is currently approved to treat DME in the U.S. and Europe.

Shares of Regeneron remain unchanged in pre-market trading this morning. The stock has rallied 20% over the past 12 months.

Will this stock be your next multi-bagger?
Give us five minutes and we'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks one stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.

 

Leo Sun has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.

 


Compare Brokers